Resource Summary Report

Generated by kravitz2 on Sep 19, 2026

B6.129-Idua^{tm1Clk}/J

RRID:IMSR_JAX:004068
Type: Organism

Proper Citation

RRID:IMSR_JAX:004068

Organism Information

URL: https://www.jax.org/strain/004068

Proper Citation: RRID:IMSR_JAX:004068

Description: Mus musculus with name B6.129-Idua^{tm1Clk}/J from IMSR.

Species: Mus musculus

Notes: gene symbol note: iduronidase; alpha-L; mutant strain|congenic strain: Idua

Affected Gene: iduronidase; alpha-L

Genomic Alteration: targeted mutation 1; Lorne A Clarke

Catalog Number: JAX:004068

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: sperm

Organism Name: B6.129-Idua^{tm1Clk}/J

Record Creation Time: 20250513T053642+0000

Record Last Update: 20260919T054832+0000

Ratings and Alerts

No rating or validation information has been found for B6.129-Idua^{tm1Clk}/J.

No alerts have been found for B6.129-Idua^{tm1Clk}/J.

Data and Source Information

Source: Integrated Animals

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at kravitz2 .

Gaffke L, et al. (2023) Actin Cytoskeleton Polymerization and Focal Adhesion as Important Factors in the Pathomechanism and Potential Targets of Mucopolysaccharidosis Treatment. Cells, 12(13).

?abi?ska M, et al. (2023) Decreased Levels of Chaperones in Mucopolysaccharidoses and Their Elevation as a Putative Auxiliary Therapeutic Approach. Pharmaceutics, 15(2).

W?sierska M, et al. (2022) Murine Fibroblasts and Primary Hepatocytes as Tools When Studying the Efficacy of Potential Therapies for Mucopolysaccharidosis Type I. International journal of molecular sciences, 24(1).

Lin Y, et al. (2020) miR-143 Regulates Lysosomal Enzyme Transport across the Blood-Brain Barrier and Transforms CNS Treatment for Mucopolysaccharidosis Type I. Molecular therapy : the journal of the American Society of Gene Therapy, 28(10), 2161.

Ghosh A, et al. (2019) Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I. Molecular therapy. Methods & clinical development, 13, 321.

Le SQ, et al. (2018) A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I. Molecular therapy. Methods & clinical development, 8, 42.

Khalid O, et al. (2016) Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I. PloS one, 11(3), e0150850.

Watson HA, et al. (2014) Heparan sulfate inhibits hematopoietic stem and progenitor cell migration and engraftment in mucopolysaccharidosis I. The Journal of biological chemistry, 289(52), 36194.